$7.00 or Nothing
1時間前
The difference between **Head of Household (HOH)** and **Married Filing Jointly (MFJ)** filing statuses lies in eligibility and tax benefits:
### Head of Household (HOH)
- **Eligibility**: You must be unmarried (or considered unmarried for tax purposes) and provide more than half the cost of maintaining a home for a qualifying dependent (e.g., a child or parent) for over half the year.
- **Tax Benefits**: HOH offers a higher standard deduction than filing as Single and places you in a more favorable tax bracket, reducing your taxable income.
- **Example**: A single parent supporting a child and paying most household expenses may qualify for HOH.
### Married Filing Jointly (MFJ)
- **Eligibility**: You must be legally married by the last day of the tax year. Both spouses combine their income and deductions on a single tax return.
- **Tax Benefits**: MFJ provides broader tax brackets and access to credits and deductions unavailable to other statuses, often resulting in lower overall tax liability.
- **Example**: A married couple with shared income and expenses typically benefits from filing jointly.
Choosing the correct status depends on your marital status, living arrangements, and financial situation. Let me know if you'd like more details!
$7.00 or Nothing
1時間前
Syngene Acquires First US Manufacturing Facility
Yet another acquisition. Tariff based this time.
Syngene Acquires First US Manufacturing Facility
The Baltimore Biologics Drug Substance facility will serve customers across human and animal health market segments.
March 10, 2025
By: Rachel Klemovitch
Syngene-New-Facility alt=
Syngene International Limited (Syngene), a global contract research, development, and manufacturing organization (CRDMO), has acquired its first biologics site in the USA – fitted with multiple monoclonal antibody (mAbs) manufacturing lines.
The facility was purchased by Syngene subsidiary Syngene USA Inc., from Emergent Manufacturing Operations Baltimore, LLC (a subsidiary of Emergent BioSolutions Inc.).
The facility will expand Syngene’s global biologics footprint to serve its customers across human and animal health market segments. The new site will increase Syngene’s total single-use bioreactor capacity to 50,000L for large molecule discovery, development, and manufacturing services.
Also, the facility will provide Syngene’s customers with continuity of supply from its four development and manufacturing facilities located in India and North America, offering services ranging from cell line development, and process optimization, as well as clinical and commercial supply.
Overall investment in the US facility is estimated at around $50 million, including the cost of acquisition ($36.5 million) and expenses to make the facility operational. The sale is expected to close in March 2025, subject to the satisfaction of customary closing conditions.
Peter Bains, CEO Designate, Syngene International Ltd., said, “With one of the largest biologics R&D teams and commercial scale manufacturing capabilities in both India and the USA, we now offer a compelling and flexible solution for global pharma and biotech customers. This investment will enable Syngene to cater to growing client requirements in an expanding market.”
Alex Del Priore, Senior Vice President – Development & Manufacturing Services, Syngene International Ltd., commented, “This facility is a significant milestone for Syngene and comes in response to growing client demand in the United States, the fastest-growing biologics market. It strengthens our offering for animal health clients looking for USDA approval for their products.”
The upgraded Baltimore facility is located near key biotech hubs in the Northeast of the US and will be available for client projects from the second half of 2025. Syngene anticipates the site will see demand from innovative US mAb developers requiring direct access for ‘onshore’ production, as well as international innovators that want a US-based manufacturing option.
As part of the agreement, Emergent has the right to secure manufacturing capacity from the facility in the future, representing offtake potential from US-based innovators. It will also support the growing animal health segment in which a US site is often a key client requirement.
NASDAQ2020
1時間前
Let’s say you are single and you make $$1,000,000 profit and you had the stock for a year or more (long term).
0% Rate:
no taxes on first $48,350 = $0.00 taxes
15% Rate:
$48,351 to $533,400 = $72,757 taxes
20% Rate:
On the rest Over $533,400 to 1 million =$93,320
Your tax liability is $166,070 federal
If you make more than $1 million it’s more.
If married or head of house hold it’s different. Above is for a single person
Hope you’re in a non tax state or they take a cut you.
Please verify all this with your tax guy. I’m not a CPA
NASDAQ2020
3時間前
For 2025 (returns normally filed in early 2026), the long-term capital gains tax rates remain at 0%, 15%, and 20%, but the income thresholds have shifted.
The new brackets are as follows:
0% Rate:
Single filers: Up to $48,350
Married filing jointly: Up to $96,700
Head of household: Up to $64,750
15% Rate:
Single filers: $48,351 to $533,400
Married filing jointly: $96,701 to $600,050
Head of household: $64,751 to $566,700
20% Rate:
Single filers: Over $533,400
Married filing jointly: Over $600,050
Head of household: Over $566,700
$2.00 or no deal
5時間前
I'm ALREADY on record stating I will NOT be accepting any deal that involves shares of another company.
I invested in ELITE, not some other douchebag company.
IN FACT, I believe it is downright ILLEGAL to be given shares of another company I did not WILLINGLY invest in.
IN ADDITION, I'm also on RECORD stating I will not accept ANY deal if Mikah still exists at the time of the buyout REGARDLESS of how high the acquisition price is because it would have been even HIGHER without douchebag Mikah AKA NasRAT.
AND FINALLY, as seen on my new alias, I will NOT be accepting a buyout price of LESS than $2.00 per share.
SO IN CONCLUSION, ALL of the following criteria MUST be met in order for me to be voting "Yes" for the buyout. If even ONE of these items is not met I will be voting a big fat "NO".
✅️ 100% cash and cash ONLY
✅️ Mikah no longer in existence - MUST sell it's Adderall ownership to Elite
✅️ $2.00 or higher PRE-reverse split
Thanks.
All these buyouts yall are posting have been cash deals. Wonder what’s coming our way 🧐